Compare Nippon India Pharma Fund vs SBI Healthcare Opportunities Fund
Nippon India Pharma Fund
EquitySectoral-Pharma
SBI Healthcare Opportunities Fund
EquitySectoral-Pharma
Risk
Very High
Very High
Rating
2.0
5.0
Min SIP Amount
₹100
₹500
Expense Ratio
1.84
1.99
NAV
₹627.72
₹584.19
Fund Started
10 May 2004
04 Jun 1999
Fund Size
₹9479.08 Cr
₹5796.42 Cr
Exit Load
Exit load of 1% if redeemed within 1 month.
Exit load of 0.50% if redeemed within 15 days
1 Year
9.72%
17.60%
3 Year
16.77%
21.64%
5 Year
11.86%
16.05%
Equity
97.99%
96.79%
Cash
2.00%
3.16%
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 12.37% |
Divi's Laboratories Ltd. | 7.00% |
Lupin Ltd. | 6.43% |
Cipla Ltd. | 6.09% |
Apollo Hospitals Enterprise Ltd. | 5.15% |
Dr. Reddy's Laboratories Ltd. | 4.93% |
Mankind Pharma Ltd. | 4.09% |
Sai Life Sciences Ltd. | 3.94% |
Ajanta Pharma Ltd. | 3.47% |
Glaxosmithkline Pharmaceuticals Ltd. | 3.31% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 12.33% |
Divi's Laboratories Ltd. | 8.17% |
Apollo Hospitals Enterprise Ltd. | 4.91% |
Acutaas Chemicals Ltd. | 4.91% |
Torrent Pharmaceuticals Ltd. | 4.72% |
Cipla Ltd. | 4.67% |
Max Healthcare Institute Ltd. | 4.31% |
Laurus Labs Ltd. | 3.96% |
Aurobindo Pharma Ltd. | 3.90% |
Aster DM Quality Care Ltd. | 3.52% |
Name
-
-
Start Date
-
-
Description
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Launch Date
10 May 2004
04 Jun 1999
